SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry (NYSE: BB) is trending on elevated retail activity ahead of its upcoming fiscal Q2 earnings report, with sentiment turning extremely bullish on expectations for a beat. Traders point to the company's historically conservative guidance as setting up potential upside to revenue, EBITDA, and EPS, echoing analyst commentary that results may come in above estimates and consensus. The QNX story anchors the bull case: the community is highlighting NVIDIA's adoption of QNX 8.0 for automotive and physical AI operating systems, the roughly $950 million QNX royalty backlog, and speculation that a Coretura/Alloy Kore design win would first become visible in backlog rather than near-term results. Bulls argue the safety-software franchise is still mispriced as the old phone business, with some expecting the stock to finally leave single digits around the report. That optimism is meeting pushback from a vocal short contingent calling the run a squeeze setup and urging shorts on every pop, while some longs are taking profits and others are pressing the company over stalled buybacks.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Anticipation of a potential VK2735 Phase 3 readout is dominating the Viking Therapeutics conversation, with traders split between claims that the obesity data is confirmed and warnings that no press release may come. Bulls frame the stock's slide  roughly a third below its run above $40, per community posts  as a short-squeeze setup given what they describe as heavy short interest, arguing VK2735 can rival Lilly's retatrutide on efficacy and durability; bears counter that a sell-the-news drop to single digits is likely, citing GI tolerability at high doses, limited oral bioavailability, potential weight regain in the maintenance study, and dilution from share sales. A parallel thread is takeover speculation: Novo Nordisk's pipeline setbacks and its statement that its balance sheet could support larger acquisitions have traders debating whether a partnership or a multibillion-dollar buyout of Viking is Novo's most viable path against Lilly, while skeptics doubt big pharma will pay up for assets with tolerability issues. Viking's plan for slower titration in Phase 3 is also being parsed as a tolerability-driven strategy.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is drawing heavy attention around a cluster of anticipated clinical catalysts, with traders most focused on a pending IDE approval for the company's Keytruda combination trial. Community discussion repeatedly cites reported 100% response rate data and median overall survival well above historical benchmarks in that program, alongside the completed enrollment of the IMPACT pancreatic cancer trial, which traders say expanded after strong physician demand, and debate over whether GBM scan readouts or an SCC trial is the bigger potential mover.

The conversation skews strongly bullish, centered on an undervaluation thesis: traders argue the market cap ignores the multi-trial pipeline, the Tolmar commercialization partnership, and the company's Alpha DaRT technology platform. Many also point to the TASE dual listing, MSCI index inclusion, and a Barclays price target increase as signs institutional attention is building, while others describe persistent short pressure and debate whether the stock's steady advance reflects disciplined accumulation. Some community members urge caution, noting short-term behavior is hard to predict and premarket moves often mean little.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

HBAR's trending conversation centers on the Senate vote to open debate on the Clarity Act, the crypto market-structure bill that would split SEC and CFTC oversight of digital assets. Traders repeatedly tie the token's attention to that vote and to expectations of new SEC rules for commodity-classified coins including HBAR, but reaction is split: bulls argue it is not the time to sell with regulatory clarity approaching, one trader cautions the vote was only a procedural step to begin debate, and others accuse both parties of stalling for political reasons, naming senators they say voted against advancing the bill. Skeptics dismiss the SEC-news spike as another "carrot on a string" pump, blaming market manipulation for the quick fade and the token's failure to reclaim the $0.08 area, while technical posters point to the 200 MA near $0.068 and an oversold RSI. A smaller group of traders links the weakness to Grayscale withdrawing its spot HBAR ETF filing, and isolated posts tout Hedera developments such as SpaceDev joining the Hedera Council, but the Clarity Act dominates the discussion.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk shares are under sharp selling pressure, and the conversation centers on how the market received the company's Capital Markets Day, where management pointed to mid-single-digit revenue growth in line with peers through 2026, a gradual pricing transition into 2027 as semaglutide faces loss of exclusivity, pipeline diversification, and capacity for larger acquisitions. Reaction is split: many traders say the market 'is not buying it,' faulting leadership ('the market clearly hates the CEO') and overreliance on a single drug, while a bearish Morgan Stanley note adds to the negative tone and some argue investors are selling simply because they see no concrete news to lift the stock. Bulls counter that there is 'no basis for the drop,' citing a single-digit P/E at historically low levels and a strong oral Wegovy launch they view as expanding the obesity market rather than cannibalizing injectables. The announced rebrand to 'Novo' drew heavy mockery, and shares down more than 17% year to date versus Eli Lilly's 6.7% gain keep frustration elevated.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

WTI crude sliding back below $100 after Saudi Arabia signaled its attacked East-West pipeline could restore roughly half its capacity within days, alongside US Central Command reporting six-month-high oil shipments through the Strait of Hormuz, is driving attention to USO. Traders are divided between those expecting further downside as de-escalation hopes build  Iranian ceasefire terms relayed through Qatar and a possible meeting between Trump and Iran's president around the UN General Assembly  and bulls arguing the futures market is ignoring a still-disrupted physical market, citing record diesel prices, Aramco's cutoff of next-month crude allocations to European refiners, and multi-week pipeline repair timelines.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta is trending on a sharp single-session surge that added roughly $200 billion in market value  its biggest one-day gain in over a year  after reports that its Muse AI agent topped U.S. iPhone and Android download charts. Muse has become the dominant talking point, with the market repricing what the app 'might become' rather than its current revenue contribution.

The community is sharply split. Bulls argue Muse is more user-friendly than ChatGPT and see the app as evidence Meta's heavy AI spending can drive real user growth and pressure OpenAI and Anthropic, with some speculating about a run toward a $2 trillion market cap and others crediting Meta with single-handedly lifting the broader tech complex. Skeptics counter that the move is disconnected from fundamentals  the app is free with no clear profit model  and many attribute the spike to gamma-squeeze, short-squeeze, or algo-driven flows rather than news, with several traders actively short or calling for a 'sell the news' fade. Privacy concerns over Meta's handling of personal data and doubts that Muse outperforms Claude or ChatGPT reinforce the bear case. Amazon's reported decision to block Muse from its retail site as an unauthorized AI agent is adding a second layer to the debate, with some users refusing to adopt the agent without Amazon access and others reading the block as a signal of how platforms view agentic AI.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending as traders clash over the stock's repeated failure to hold gains and clear the ~$50 area even as the Nasdaq rallies: longs point to elevated short interest and squeeze potential while alleging market-maker suppression, and other traders are shorting the name outright. The debate is framed around IREN's Bitcoin-mining-to-AI/HPC data-center pivot, which bulls cite as the long-term growth story behind their conviction.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY is trending after the S&P 500 benchmark posted its first close above 765.41 and rapidly climbed from the 750 area to repeated tests of the 775 level, with the dominant community thread being a debate over what is driving the record-setting surge and whether it can hold. Skeptics feature prominently, attributing the rally to a short squeeze, options/gamma flows, or outright manipulation, and pointing to warning signs such as more stocks hitting new lows than new highs, the equal-weight index lagging the tech-heavy Nasdaq, and an absence of dark-pool buying confirmation. Many traders say they are positioned or looking to short, while bulls counter that the market keeps grinding higher no matter the headline and see room for further gains. The debate intensified because the tape shrugged off otherwise bearish catalysts  an Iranian offer to reopen the Strait of Hormuz that many traders dismissed as posturing, a Fed official's call for more rate hikes to curb inflation, and record diesel prices  while AI-driven strength in mega-cap tech lifting the Nasdaq to record highs is the most frequently cited fundamental explanation for the move.

Maase, Inc. operates as a integrated provider and operator of artificial intelligence (AI) centric full-scene digital systems. The firm focus on areas of flexible energy deployment and intelligent commercial network operation, and provide closed-loop solutions from computing infrastructure, smart hardware and full-scene services, aiming to achieve large-scale implementation of AI technologies across industries. The company was founded by Hai Feng Yu on August 6, 2018 and is headquartered in Qingdao, China.

Maase Inc. - Ordinary Shares - Class A

Highest Performances Holdings Inc. - ADR

MAAS is drawing attention on a steady stream of AI business announcements layered over a sharp technical move on expanding volume. Traders are focused on a run of signed enterprise AI services contracts  token-based agreements, an RMB1.65 million deal the company says was delivered, accepted, and paid in full, an RMB7.68 million agreement, and an RMB10 million-plus Zhongchuang Liankong contract targeted for Q3 delivery  along with its Lingyan Miaoyu LLM, a consumer access portal, and an AI security white paper. Bulls argue the string of small but confirmed contracts, plus subsidiary Huazhi Future's energy-infrastructure and robotics work, signals a genuine platform building across compute, models, and industry deployments, with some citing a strong balance sheet and growing ARR. Skeptics counter by asking why the stock fell on positive news and want volume and short-interest confirmation before chasing a violent small-cap move. Other traders frame the activity as a catalyst-scanner-momentum feedback loop in a low-float name that has outperformed the broader Hong Kong tech tape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


ae888sound

AE888